Recent Updates in the Treatment of Chronic Lymphocytic Leukemia: Year in Review 2022 - Episode 2

Selecting the Appropriate BTK Inhibitor for Frontline Treatment of CLL

, , ,

Catherine Coombs, MD, reviews data on BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in the first-line treatment of CLL, and how she approaches selecting the appropriate BTK inhibitor in practice.